Could an antidepressant ease long COVID fatigue?
NCT ID NCT07359482
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether fluvoxamine, an antidepressant, can reduce severe fatigue and other symptoms in people with post-COVID. 160 adults aged 18-70 with long-lasting fatigue after COVID will receive either the drug or a placebo for 12 weeks. The goal is to see if it improves energy and thinking, and to understand how it works in the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam UMC
RECRUITINGAmsterdam-Zuidoost, 1105 AZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Zapping the brain to clear long COVID fog: a new hope?
- Diet and exercise may ease long COVID symptoms in obese veterans
- New program aims to help Long-COVID patients with online screening and personal support
- Breathing battle: which device helps CP Kids' lungs after COVID?
- Cold water splash: new study tests hydrotherapy for long COVID relief